1887
Volume 2024, Issue 4
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Background: Leishmaniasis is an emerging tropical infectious disease in Qatar. It is caused by the protozoan parasite of the genus, which is endemic in many regions of the world, including the Middle East. In Qatar, there is limited data about this disease, which is hindering the efficient planning and implementation of disease prevention and control measures. Therefore, to address this knowledge gap, we conducted a retrospective study to gather information on the prevalence, clinical characteristics, as well as outcomes of leishmaniasis treatment. The primary objective of this study is to provide a comprehensive analysis of leishmaniasis cases in Qatar over seven years (2016–2022). The findings of this study offer valuable insights that can guide the development of a national registry and treatment program for leishmaniasis in Qatar.

Methods: Using a retrospective cross-sectional study design, clinical and epidemiological data of all documented cases of leishmaniasis in Qatar between 2016 and 2022 were collected from electronic medical records at Hamad Medical Corporation (HMC).

Results: A total of sixty-eight cases of leishmaniasis were detected in Qatar between 2016 and 2022. Males were predominant (69.12%) with a median age of 33 years. Our study revealed a higher incidence of leishmaniasis among individuals of Syrian nationality, followed by Pakistani and Sudanese, thus promoting further investigation into the underlying factors contributing to this health disparity. Our findings revealed important epidemiological trends, highlighted key clinical characteristics, identified risk factors associated with susceptibility to leishmaniasis, and reported treatment outcomes.

Conclusion: This retrospective study presents the first comprehensive analysis of leishmaniasis in Qatar, shedding light on the epidemiology, clinical characteristics, and treatment outcomes of the disease. The data generated from this study can serve as a guide for authorities in establishing a national registry and treatment program for leishmaniasis in Qatar. Implementing these measures will contribute to the effective management and control of leishmaniasis, ultimately improving patient outcomes and public health in the country.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2024.51
2024-12-26
2025-01-10
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2024/4/qmj.2024.51.html?itemId=/content/journals/10.5339/qmj.2024.51&mimeType=html&fmt=ahah

References

  1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al.. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012; 7:(5):e35671. https://doi.org/10.1371/journal.pone.0035671
    [Google Scholar]
  2. Jones TC, Johnson WD Jr, Barretto AC, Lago E, Badaro R, Cerf B, et al.. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis. 1987; 156:73. https://doi.org/10.1093/infdis/156.1.73
    [Google Scholar]
  3. World Health Organization. Essential leishmaniasis maps. Available from: http://www.who.int/leishmaniasis/leishmaniasis_maps/en/ (accessed September 6, 2012).
    [Google Scholar]
  4. Dowlati Y. Cutaneous leishmaniasis: Clinical aspect. Clin Dermatol. 1996; 14:425. https://doi.org/10.1016/0738-081x(96)00058-2
    [Google Scholar]
  5. Dimier-David L, David C, Muñoz M, Vargas F, Bustillos R, Valda L, et al.. Epidemiological, clinical and biological features of mucocutaneous leishmaniasis in Bolivia after a 221 patient sample. Bull Soc Pathol Exot. 1993; 86:106.
    [Google Scholar]
  6. Bogdan C. Leishmaniasis in rheumatology, haematology and oncology: Epidemiological, immunological and clinical aspects and caveats. Ann Rheum Dis. 2012; 71:Suppl 2:i60. https://doi.org/10.1136/annrheumdis-2011-200596
    [Google Scholar]
  7. Marovich MA, Lira R, Shepard M, Fuchs GH, Kruetzer R, Nutman TB, et al.. Leishmaniasis recidivans recurrence after 43 years: A clinical and immunologic report after successful treatment. Clin Infect Dis. 2001; 33:(7):1076. https://doi.org/10.1086/322643
    [Google Scholar]
  8. Knight CA, Harris DR, Alshammari SO, Gugssa A, Young T, Lee CM. Leishmaniasis: Recent epidemiological studies in the Middle East. Front Microbiol. 2023; 13:1052478. https://doi.org/10.3389/fmicb.2022.1052478
    [Google Scholar]
  9. Abuzaid AA, Aldahan MA, Al Helal MA, Assiri AM, Alzahrani MH. Visceral leishmaniasis in Saudi Arabia: From hundreds of cases to zero. Acta Trop. 2020; 212:105707. https://doi.org/10.1016/j.actatropica.2020.105707
    [Google Scholar]
  10. Ihsanullah M, Yousuf MJ, Ahmad N, Masood Z, Majeed S, Hassan HU, et al.. Prevalence of cutaneous leishmaniasis in the largest populated city Karachi, Pakistan. Braz J Biol. 2021; 83:e247583. https://doi.org/10.1590/1519-6984.247583
    [Google Scholar]
  11. Planning and Statistic Authority. Qatar. Available from: https://www.psa.gov.qa/en/statistics1/pages/default.aspx Population of Qatar.
    [Google Scholar]
  12. Population of Qatar by Nationality – 2017 report (accessed February 7, 2017).
    [Google Scholar]
  13. Akhoundi M, Kuhls K, Cannet A, Votýpka J, Marty P, Delaunay P, et al.. A historical overview of the classification, evolution, and dispersion of Leishmania parasites and sandflies. PLoS Negl Trop Dis. 2016; 10:(3):e0004349. https://doi.org/10.1371/journal.pntd.0004349
    [Google Scholar]
  14. Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al.. Diagnosis and treatment of leishmaniasis: Clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016; 63:(12):e202. https://doi.org/10.1093/cid/ciw742
    [Google Scholar]
  15. WHO Technical Report Series 949. Control of the leishmaniases. 2010. Available from: http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf (accessed September 4, 2012).
    [Google Scholar]
  16. Epidemiology and Risk Factors. Leishmaniasis – CDC. Available from: https://www.cdc.gov/parasites/leishmaniasis/epi.html
    [Google Scholar]
  17. Despommier DD, Griffin DO, Gwadz RW, Hotez PJ, Knirsch CA. Parasitic diseases. 7th ed. New YorkParasites without Borders, Inc.2019.
    [Google Scholar]
  18. Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al.. Diagnosis and treatment of leishmaniasis. CID. 2016:63.
    [Google Scholar]
  19. Tabbabi A. Review of leishmaniasis in the Middle East and North Africa. Afri Health Sci. 2019; 19:(1):1329-37. https://doi.org/10.4314/ahs.v19i1.4
    [Google Scholar]
  20. Gwida M, Al Dahouk S, Melzer F, Rösler U, Neubauer H, Tomaso H. Brucellosis - regionally emerging zoonotic disease? Croat Med J. 2010; 51:289-95. https://doi.org/10.3325/cmj.2010.51.289
    [Google Scholar]
  21. Isenring E, Fehr J, Gültekin N, Schlagenhauf P. Infectious disease profiles of Syrian and Eritrean migrants presenting in Europe: A systematic review. Travel Med Infect Dis. 2018; 25:65-76. https://doi.org/10.1016/j.tmaid.2018.04.014
    [Google Scholar]
  22. Ullah W, Khan A, Niaz S, Al-Garadi MA, Nasreen N, Swelum AA, et al.. Epidemiological survey, molecular profiling and phylogenetic analysis of cutaneous leishmaniasis in Khyber Pakhtunkhwa, Pakistan. Trans R Soc Trop Med Hyg. 2024; 118:(4):273-86. https://doi.org/10.1093/trstmh/trad086
    [Google Scholar]
  23. Riebenbauer K, Czerny S, Egg M, Urban N, Kinaciyan T, Hampel A, et al.. The changing epidemiology of human leishmaniasis in the non-endemic country of Austria between 2000 to 2021, including a congenital case. PLOS Negl Trop Dis. 2024; 18:(1):e0011875. https://doi.org/10.1371/journal.pntd.0011875
    [Google Scholar]
  24. Naeem AT, Mahmoudi S, Saboui F, Hajjaran H, Pourakbar B, Mohebal M, et al.. Clinical features and laboratory findings of visceral leishmaniasis in children referred to Children Medical Center Hospital, Tehran, Iran during 2004–2011. Iran J Parasitol. 2014; 9:(1):1-5.
    [Google Scholar]
  25. Scarpini S, Dondi A, Totaro C, Biagi C, Melchionda F, Zama D, et al.. Visceral leishmaniasis: Epidemiology, diagnosis, and treatment regimens in different geographical areas with a focus on pediatrics. Microorganisms. 2022; 10:(10):1887. https://doi.org/10.3390/microorganisms10101887
    [Google Scholar]
  26. Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL. Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? Int J Parasitol Drugs Drug Resist. 2012; 2:11-9. https://doi.org/10.1016/j.ijpddr.2012.01.003
    [Google Scholar]
  27. Mirzabeigi M, Farooq U, Baraniak S, Dowdy L, Ciancio G, Vincek V. Reactivation of dormant cutaneous Leishmania infection in a kidney transplant patient. J Cutan Pathol. 2006; 33:701. https://doi.org/10.1111/j.1600-0560.2006.00532.x
    [Google Scholar]
  28. Omollo R, Alexander N, Edwards T, Khalil EAG, Younis BM, Abuzaid AA, et al.. Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: Study protocol for a randomized controlled trial. Trials. 2011; 12:166. https://doi.org/10.1186/1745-6215-12-166
    [Google Scholar]
  29. Yeshaw Y, Tsegaye AT, Nigatu SG. Incidence of mortality and its predictors among adult visceral leishmaniasis patients at the University of Gondar Hospital: A retrospective cohort study. Infect Drug Resist. 2020; 13:881-91. https://doi.org/10.2147/IDR.S245991
    [Google Scholar]
  30. White AC Jr, Coyle CM, Rajshekhar V, Singh G, Hauser WA, Mohanty A, et al.. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2018; 66:(8):e49-75. https://doi.org/10.1093/cid/cix1084
    [Google Scholar]
/content/journals/10.5339/qmj.2024.51
Loading
/content/journals/10.5339/qmj.2024.51
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): clinical characteristicsepidemiologyleishmaniasis and treatment outcomes
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error